Antibodies have tremendous impact in the clinic, in diagostics and in research. Nanobodies (discovered in Belgium) are small 15 kDa antibodies with huge potential in diagnostics and therapeutics. They surpass conventional IgGs.
Nanobody cDNA is always available, economizing recombinant production. We derivatize nanobodies for site-specific ADC development, for generating nuclear tracers, coupling to biologicals.
Clinical trials with nanobodies are ongoing in the context of CAR-T, chimeric antigen receptor T cell therapy. They are also emerging in the context of vaccine development. Nanobodies are an ideal stepping stone towards drug development. They 'scan' the surface of a target protein and detect sensitive/druggable regions in proteins. An ideal instrument against ‘undruggable’ targets.
Gulliver Biomed is your partner for nanobody development against any protein. 40 research papers published, > 15 years experience. Technology transfer possible.